Ligand Pharmaceuticals | LGND - Operating Expenses


Ligand Pharmaceuticals reported $55.1M in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
Agenus USD -221.22M 241.03M Mar/2026
Amgen USD 11.69B 6.9B Jun/2026
Anika Therapeutics USD 137.28M 3.38M Jun/2026
Arrowhead Research USD 215M 8.23M Mar/2026
Baxter International USD 2.68B 3.36B Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Eli Lilly USD 10.52B 496M Jun/2026
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
Enviri Corporation USD 233.18M 357.11M Mar/2026
Gilead Sciences USD 3.95B 19.57B Jun/2026
GlaxoSmithKline GBP 5.8B 468M Jun/2026
Glaxosmithkline GBP 5.34B 3.83B Mar/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Insmed USD 526.79M 20.55M Jun/2026
Intrexon USD 61.56M 26.1M Jun/2024
Ionis Pharmaceuticals USD 370.24M 6.24M Jun/2026
Karyopharm Therapeutics USD 61.83M 9.9M Mar/2026
Ligand Pharmaceuticals USD 55.1M 20.75M Jun/2026
MacroGenics USD 21.2M 32.13M Mar/2026
Merck USD 15.77B 2.4B Jun/2026
Pacira USD 180.54M 7.79M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Veracyte USD 126.36M 6.37M Jun/2026